OSE Immunotherapeutics and the Nantes University Hospital Center present a positive interim analysis of the Phase 1/2 FIRsT clinical trial evaluating FR104/VEL-101 immunotherapy in kidney transplantation – 11/12/2023 at 07:30

At the annual congress of the Société Francophone de Transplantation
Supported by the European Society of Organ Transplantation (ESOT)

Nantes, France – December 11, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and the Nantes University Hospital Center presented a positive interim analysis of data from the first use in kidney transplantation of the anti-CD28 FR104/VEL-101 at the Annual Congress of the Société Francophone de Transplantation (SFT) held in Brest (December 5 – 8, 2023).